These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 28434321)

  • 1. Renal outcomes of autologous stem cell transplantation among patients with light-chain amyloidosis: a single centre Spanish experience.
    Azorín SE; Cibeira MT; Solé M; Fernández de Larrea C; Rosiñol L; Rovira M; Campistol JM; Bladé J
    Amyloid; 2017 Mar; 24(sup1):70-71. PubMed ID: 28434321
    [No Abstract]   [Full Text] [Related]  

  • 2. Urinary albumin to creatinine ratio in diagnosis and risk stratification of renal AL amyloidosis.
    Palladini G; Milani P; Basset M; Russo F; Lavatelli F; Nuvolone M; Ferraro G; Bozzola M; Foli A; Merlini G
    Amyloid; 2017 Mar; 24(sup1):68-69. PubMed ID: 28434326
    [No Abstract]   [Full Text] [Related]  

  • 3. Outcomes from Autologous Hematopoietic Cell Transplantation versus Chemotherapy Alone for the Management of Light Chain Amyloidosis.
    Oke O; Sethi T; Goodman S; Phillips S; Decker I; Rubinstein S; Concepcion B; Horst S; Jagasia M; Kassim A; Harrell SL; Langone A; Lenihan D; Rawling KT; Slosky D; Cornell RF
    Biol Blood Marrow Transplant; 2017 Sep; 23(9):1473-1477. PubMed ID: 28546074
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification and quantification of urinary monoclonal proteins by capillary electrophoresis in AL amyloidosis.
    Russo F; Valentini V; Basset M; Bosoni T; Milani P; Ferraro G; Pirolini L; Foli A; Lavatelli F; Belvisi F; Consogno G; Nuvolone M; Li Bergolis F; Bozzola M; Albertini R; Palladini G; Merlini G
    Amyloid; 2017 Mar; 24(sup1):66-67. PubMed ID: 28434323
    [No Abstract]   [Full Text] [Related]  

  • 5. Light chain type predicts organ involvement and survival in AL amyloidosis patients receiving stem cell transplantation.
    Sidiqi MH; Aljama MA; Muchtar E; Buadi FK; Warsame R; Lacy MQ; Dispenzieri A; Dingli D; Leung N; Gonsalves WI; Kumar SK; Kapoor P; Kourelis TV; Hogan WJ; Gertz MA
    Blood Adv; 2018 Apr; 2(7):769-776. PubMed ID: 29615413
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term outcomes of renal AL amyloidosis patients undergoing autologous stem cell transplantation: Validating the performance of the renal staging system.
    Muchtar E; Gertz MA; Mwangi R; Hassan H; Dispenzieri A; Leung N; Buadi FK; Dingli D; Staron A; Sanchorawala V
    Am J Hematol; 2024 Nov; 99(11):2118-2126. PubMed ID: 39207186
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Progressive renal light chain amyloidosis with the absence of detectable free monoclonal light chains after an autologous hematopoietic stem cell transplant for amyloid light chain amyloidosis.
    Roth RM; Benson D; Hebert LA; Bissell MG; Satoskar AA; Nadasdy T; Brodsky SV
    Arch Pathol Lab Med; 2013 Sep; 137(9):1304-8. PubMed ID: 23991744
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment With Bortezomib-based Therapy, Followed by Autologous Stem Cell Transplantation, Improves Outcomes in Light Chain Amyloidosis: A Retrospective Study.
    Jain T; Kosiorek HE; Kung ST; Shah VS; Dueck AC; Gonzalez-Calle V; Luft S; Reeder CB; Adams R; Noel P; Larsen JT; Mikhael J; Bergsagel L; Stewart AK; Fonseca R
    Clin Lymphoma Myeloma Leuk; 2018 Jul; 18(7):486-492.e1. PubMed ID: 29753692
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The impact of dialysis on the survival of patients with immunoglobulin light chain (AL) amyloidosis undergoing autologous stem cell transplantation.
    Leung N; Kumar SK; Glavey SV; Dispenzieri A; Lacy MQ; Buadi FK; Hayman SR; Dingli D; Kapoor P; Zeldenrust SR; Russell SJ; Lust JA; Hogan WJ; Rajkumar SV; Gastineau DA; Kourelis TV; Lin Y; Gonsalves WI; Go RS; Gertz MA
    Nephrol Dial Transplant; 2016 Aug; 31(8):1284-9. PubMed ID: 26627634
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictive value of the new renal response criteria in AL amyloidosis treated with high dose melphalan and stem cell transplantation.
    Havasi A; Doros G; Sanchorawala V
    Am J Hematol; 2018 May; 93(5):E129-E132. PubMed ID: 29430701
    [No Abstract]   [Full Text] [Related]  

  • 11. Clinical and laboratory profile of renal amyloidosis: A single-center experience.
    Engineer DP; Kute VB; Patel HV; Shah PR
    Saudi J Kidney Dis Transpl; 2018; 29(5):1065-1072. PubMed ID: 30381502
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictors and outcomes of acute kidney injury during autologous stem cell transplantation in AL amyloidosis.
    Nader R; Zhen A; Angel-Korman A; Pavlovich SS; Pogrebinsky A; Doros G; Menn-Josephy H; Stern L; Sanchorawala V; Havasi A
    Nephrol Dial Transplant; 2022 Jun; 37(7):1281-1288. PubMed ID: 34043009
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Autologous Hematopoietic Cell Transplantation Versus Chemotherapy Alone for Immunoglobulin Light Chain Amyloidosis: A Retrospective Study.
    Miyazaki K; Suzuki K
    Clin Lymphoma Myeloma Leuk; 2019 Jul; 19(7):413-422.e5. PubMed ID: 31023593
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prolonged renal survival in light chain amyloidosis: speed and magnitude of light chain reduction is the crucial factor.
    Rezk T; Lachmann HJ; Fontana M; Sachchithanantham S; Mahmood S; Petrie A; Whelan CJ; Pinney JH; Foard D; Lane T; Youngstein T; Wechalekar AD; Bass P; Hawkins PN; Gillmore JD
    Kidney Int; 2017 Dec; 92(6):1476-1483. PubMed ID: 28729034
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term prognosis of AL and AA renal amyloidosis: a Japanese single-center experience.
    Ozawa M; Komatsuda A; Ohtani H; Nara M; Sato R; Togashi M; Takahashi N; Wakui H
    Clin Exp Nephrol; 2017 Apr; 21(2):212-227. PubMed ID: 27116248
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Light-chain amyloidosis with renal involvement: renal outcomes and validation of two renal staging systems in the Chinese population.
    Zhu Z; Yue C; Sun Y; Li X; Li M
    Amyloid; 2019 Dec; 26(4):186-191. PubMed ID: 31339366
    [No Abstract]   [Full Text] [Related]  

  • 17. Outcomes of t(11;14) light chain (AL) amyloidosis after autologous stem cell transplantation: benchmark for new therapies.
    Bal S; Estrada-Merly N; Costa LJ; Qazilbash MH; Kumar S; D'Souza A
    Blood Cancer J; 2023 Nov; 13(1):170. PubMed ID: 37968258
    [No Abstract]   [Full Text] [Related]  

  • 18. Outcomes of autologous hematopoietic cell transplantation in primary amyloidosis after bortezomib-based induction therapy.
    Hong S; Valent J; Rybicki L; Abounader D; Bolwell B; Dean R; Gerds AT; Jagadeesh D; Hamilton BK; Hill B; Kalaycio ME; Pohlman B; Reu F; Samaras C; Sobecks R; Majhail NS; Liu HD
    Bone Marrow Transplant; 2016 May; 51(5):732-4. PubMed ID: 26726941
    [No Abstract]   [Full Text] [Related]  

  • 19. Evolving Role of Autologous Stem Cell Transplantation for Light Chain Amyloidosis in the Modern Era.
    Baljevic M
    Oncology (Williston Park); 2021 Aug; 35(8):474-475. PubMed ID: 34398595
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of propylene glycol-free melphalan conditioning in light-chain amyloidosis patients undergoing autologous hematopoietic cell transplantation is well tolerated and effective.
    Badar T; Hari P; Chhabra S; Dhakal B; Drobyski WR; Fenske TS; Hamadani M; Pasquini M; Saber W; Shah NN; Shaw BE; D'Souza A
    Bone Marrow Transplant; 2018 Sep; 53(9):1210-1213. PubMed ID: 29679076
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.